• 30 Hits
  • 検索条件 : 絞込み (MeSH = Ovarian Neoplasms / drug therapy*)
生物種 リソース名 タイトル
ヒト・動物細胞 KGN(RCB1154) Procaspase-Activating Compound-1 Synergizes with TRAIL to Induce Apoptosis in Established Granulosa Cell Tumor Cell Line (KGN) and Explanted Patient Granulosa Cell Tumor Cells In Vitro.
ヒト・動物細胞 JHOM-1(RCB1676) , JHOM-2B(RCB1682) Dual inhibition of phosphatidylinositol 3'-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach for mucinous adenocarcinoma of the ovary.
ヒト・動物細胞 JHOC-5(RCB1520) Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers.
ヒト・動物細胞 JHOS-2(RCB1521) , JHOC-5(RCB1520) CHD4 regulates platinum sensitivity through MDR1 expression in ovarian cancer: A potential role of CHD4 inhibition as a combination therapy with platinum agents.
ヒト・動物細胞 KGN(RCB1154) Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells.
ヒト・動物細胞 HHUA(RCB0658) Growth-inhibitory signals by activin A do not affect anticancer drug-sensitivity and acquired multi-drug-resistance in human ovarian endometrioid adenocarcinoma OVK-18 cells.
ヒト・動物細胞 HHUA(RCB0658) Novel target genes responsive to the anti-growth activity of triptolide in endometrial and ovarian cancer cells.
ヒト・動物細胞 HHUA(RCB0658) PK11195 enhances chemosensitivity to cisplatin and paclitaxel in human endometrial and ovarian cancer cells.
ヒト・動物細胞 JHOS-2(RCB1521) , JHOS-4(RCB1678) Divergent metabolic responses dictate vulnerability to NAMPT inhibition in ovarian cancer.
ヒト・動物細胞 JHOC-7(RCB1688) , JHOC-9(RCB2226) Effect of murine double-minute 2 inhibitors in preclinical models of advanced clear cell carcinomas originating from ovaries and kidneys.
ヒト・動物細胞 OVK18(RCB1903) , JHOC-5(RCB1520) , JHOC-7(RCB1688) , JHOC-8(RCB1723) , JHOC-9(RCB2226) , JHOS-2(RCB1521) , JHOS-4(RCB1678) Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models.
ヒト・動物細胞 OV2944-HM-1(RCB1483) Anti-VEGF therapy resistance in ovarian cancer is caused by GM-CSF-induced myeloid-derived suppressor cell recruitment.
ヒト・動物細胞 JHOC-5(RCB1520) , JHOC-7(RCB1688) , JHOC-9(RCB2226) Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase-Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type.
ヒト・動物細胞 JHOC-7(RCB1688) Anti-tumor activity of dual inhibition of phosphatidylinositol 3-kinase and MDM2 against clear cell ovarian carcinoma.
ヒト・動物細胞 OVK18(RCB1903) Oncogenic and drug-sensitive RET mutations in human epithelial ovarian cancer.
ヒト・動物細胞 JHOC-9(RCB2226) Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma.
ヒト・動物細胞 JHOC-5(RCB1520) Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma.
ヒト・動物細胞 JHOS-2(RCB1521) , JHOS-3(RCB1546) , JHOS-4(RCB1678) Histone methyltransferase SMYD2 selective inhibitor LLY-507 in combination with poly ADP ribose polymerase inhibitor has therapeutic potential against high-grade serous ovarian carcinomas.
ヒト・動物細胞 JHUEM-2(RCB1551) Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers.
ヒト・動物細胞 JHOC-5(RCB1520) ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors.